Results 21 to 30 of about 175,837 (263)
The DEAD/DEAH box helicase, DDX11, is essential for the survival of advanced melanomas
Molecular Cancer, 2012 Background Despite continuous efforts to identify genes that are pivotal regulators of advanced melanoma and closely related to it, to determine which of these genes have to be blocked in their function to keep this highly aggressive disease in check, it
Bhattacharya Chitralekha +2 more
doaj +1 more source
Current Oncology, 2022 Nine drugs have been marketed for 10 years for the treatment of advanced melanoma (AM). With half of patients reaching a second line, the optimal sequence of treatments remains unclear.
Marguerite Kandel +26 more
doaj +1 more source
Frontiers in Oncology, 2021 Combination immunotherapy can overcome the limited objective response rates of PD-1 blockade. Interferon alpha (IFN-α) has been proven to be effective in modulating immune responses and may enhance the clinical responses to PD-1 blockade.
Dong-Dong Jia +5 more
doaj +1 more source
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
Frontiers in Medicine, 2019 Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced ...
Taku Fujimura +19 more
doaj +1 more source
Frontiers in Oncology, 2023 ObjectiveTo investigate risk factors for advanced melanoma over 50 years of age and to develop and validate a new line chart and classification system.MethodsThe SEER database was screened for patients diagnosed with advanced melanoma from 2010 to 2019 ...
Qiufen Xi +5 more
doaj +1 more source
Frontiers in Oncology, 2020 Recent development of integrative therapy against melanoma combines surgery, radiotherapy, targeted therapy, and immunotherapy; however, the clinical outcomes of advanced stage and recurrent melanoma are poor.
Yanfeng Cheng, Peng Shen
doaj +1 more source
Advances in the Immunobiological Therapies for Advanced Melanoma
Actas Dermo-Sifiliográficas (English Edition), 2017 Metastatic or locally advanced unresectable melanoma carries a high morbidity and mortality. However, notable advances have been made in recent years in the systemic treatment of this disease, with the appearance of targeted therapy using tyrosine kinase inhibitors that block the mitogen activated protein kinase pathway, and of modern immunotherapy ...
M C, Pérez Gago +2 more
openaire +2 more sources
Melanoma Management, 2018 Introduction: Immunotherapies, including checkpoint inhibitors (CIs) such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) inhibitors, are revolutionizing the treatment of advanced melanoma.
Elizabeth S Mearns +6 more
doaj +1 more source
Treatment of Advanced Metastatic Melanoma
Dermatology Practical & Conceptual, 2021 The introduction in clinical practice of new drug compounds both targeted therapies anti-BRAF and checkpoint inhibitors have largely improved our potential to manage advanced metastatic melanoma patients. This has led to a significant improvement in terms of response rates and particularly in the overall survival (OS).
Pietro Quaglino +5 more
openaire +3 more sources
Case Reports in Oncology, 2020 Immune checkpoint inhibitors (ICIs) significantly prolong survival in patients with metastatic melanoma but can lead to serious immune-related adverse events.
Yumi Kambayashi +5 more
doaj +1 more source